The pendulum of prostate cancer screening

JAMA - Journal of the American Medical Association

Volumn 314, Issue 19, 2015, Pages 2031-2033

  Penson, David F ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CANCER STATISTICS; DISEASE ASSOCIATION; EDITORIAL; FOLLOW UP; HEALTH CARE PLANNING; HIGH RISK PATIENT; HUMAN; MANAGEMENT STYLE; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SELF REPORT; SWEDEN; UNITED STATES; BLOOD; MALE; PROSTATIC NEOPLASMS;

HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84947466218     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.13775     Document Type: Editorial

References (17)

1. Moyer VA; US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-134.
2. Andriole GL, Crawford ED, Grubb RL, et al; PLCO Project Team. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012; 104(2):125-132.
3. Schrder FH, Hugosson J, Roobol MJ, et al; ERSPC Investigators. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959): 2027-2035.
4. Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC, Berg C. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials. 2010;7(4):303-311.
5. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Gteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11(8):725-732.
6. Mohler JL, Kantoff PW, Armstrong AJ, et al; National Comprehensive Cancer Network. Prostate cancer, version 2. 2014. J Natl Compr Canc Netw. 2014;12(5):686-718.
7. CooperbergMR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990-2013. JAMA. 2015;314(1):80-82.
8. Sammon JD, Abdollah F, Choueiri TK, et al. Prostate-specific antigen screening after 2012 US Preventive Services Task Force recommendations. JAMA. doi:10.1001/jama. 2015. 7273.
9. Jemal A, Fedewa SA, Ma J, et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA. doi:10 . 1001/jama. 2015. 14905
10. Gulati R, Mariotto AB, Chen S, Gore JL, Etzioni R. Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. J Clin Epidemiol. 2011;64(12):1412-1417.
11. Heijnsdijk EAM, Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med. 2012;367(7):595-605.
12. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374-383.
13. Barry MJ, Hayes JH. Evaluating an elevated screening PSA test. JAMA. doi:10.1001/jama . 2015. 12614.
14. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA Guideline. J Urol. 2013;190(2):419-426.
15. Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med. 2013;158(3):145-153.
16. Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ. 2013;346:f2023.
17. Ankerst DP, Boeck A, Freedland SJ, et al. Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol. 2012;30(2):181-187.